If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.55
Bid: 8.50
Ask: 8.60
Change: -0.14 (-1.59%)
Spread: 0.10 (1.176%)
Open: 8.58
High: 8.66
Low: 8.55
Prev. Close: 8.66
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Solar Foods Completes EURO 8m Series B Financing

16 Nov 2023 14:05

RNS Number : 7325T
Agronomics Limited
16 November 2023
 

16 November 2023

Agronomics Limited

("Agronomics" or the "Company")

Solar Foods Completes ?8 million Series B Financing

 

Agronomics (LSE:ANIC), a leading listed company focused on the field of cellular agriculture, is pleased to announce that portfolio company Solar Foods Oy ("Solar Foods") has raised ?8 million in a Series B financing round carried out through the Finnish-based investment organizer Springvest Oyj ("Springvest"). In addition, existing investors participated in the Series B financing alongside Springvest via a private placement anticipated to close within 2 weeks. The private placement includes existing investors Happiness Capital, Lifeline Ventures, VTT Ventures and Fazer. The Series B funds will be used for continued building and ramping up production of their single cell protein SoleinTM.

 

Since Agronomics' first investment in Solar Foods, significant technical, regulatory, and operational progress has been made. This includes a substantial increase in the productivity of SolarFoods' organism by over 10x, achieving regulatory approval of SoleinTM in Singapore and submission of a dossier to the European Food Safety Authority for approval in the European Union. In December 2022, Solar Foods received ?34 million in grant funding to support the construction of its first commercial scale facility, Factory 01, which management understands is currently scheduled to be operational in the first half of 2024.

 

Agronomics has invested, in aggregate, ?6 million in Solar Foods, being a ?3 million investment in Solar Foods Series A round in September 2020 and ?3 million in the form of a pre-Series B Convertible Promissory Note ("CPN") in October 2021. Subject to audit, the Company's 2020 Series A investment will be carried at a book value of £8.3 million including an uplift of £5.7 million. The Company expects to convert the CPN following the closing of the private placement, at which point a further announcement will be made.

 

A link to the Solar Foods announcement is as follows: https://solarfoods.com/solar-foods-share-issue-oversubscribed/

 

About Solar Foods

Solar Foods produces protein using carbon dioxide and electricity. SoleinTM production, irrespective of weather and climate conditions, liberates global protein production from the constraints of traditional agriculture. Solar Foods, founded in 2017 in Espoo, Finland by Dr Pasi Vainikka, Dr Juha-Pekka Pitkänen, Sami Holmström, Jari Tuovinen, Professor Jero Ahola, and Janne Mäkelä as a spinoff from VTT Technical Research Centre of Finland and LUT University. www.solarfoods.com.

 

About SoleinTM

SoleinTM is a microbial protein-rich powder that contains all the essential amino acids. It is produced using a bioprocess where microbes are fed with gases, including carbon dioxide, hydrogen, and oxygen, together with small amounts of nutrients. The bioprocess resembles winemaking, with carbon dioxide and hydrogen replacing sugar as the source of carbon and energy.

This type of production method has the potential to transform the sustainability, availability, and transparency of what we eat and where food can be produced. It is not reliant on agriculture, weather, or climate: it can be produced in harsh conditions such as deserts, Arctic areas, even space. Learn more about SoleinTM at www.solein.com.

About Agronomics

Agronomics is the leading listed venture capital firm with a focus on cellular agriculture. The Company has established a portfolio of over 20 holdings at the Pre-Seed to Series C stage in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population.

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

 

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change, facilitated by advances in cellular agriculture. This change is necessary, given scientists' claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5?.

 

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This, combined with the Good Food Institute's estimate that a US $1.8 trillion investment is needed to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however, it is still less than US$ 5 billion - the amount invested worldwide since the industry's inception in 2016.

For further information please contact:

Agronomics

Limited

Beaumont

Cornish Limited

Canaccord Genuity Limited

Cavendish Securities Plc

Peterhouse Capital

Limited

SEC Newgate

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Rees

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Lucy Williams

Charles Goodfellow

Bob Huxford

George Esmond

Anthony Hughes

Alice Cho

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

agronomics@secnewgate.co.uk

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBSBDBDGBDGXL
Date   Source Headline
23rd Dec 201612:00 pmRNSFinal Results and Notice of AGM
22nd Dec 20162:41 pmRNSLoan to the Diabetic Boot Company Ltd
12th Oct 20167:00 amRNSNet Asset Value(s)
22nd Jul 20167:00 amRNSNet Asset Value(s)
29th Apr 20167:00 amRNSNet Asset Value calculation to 31 March 2016
15th Apr 20167:00 amRNSChange of Adviser
18th Mar 20167:00 amRNSHolding(s) in Company
17th Mar 20167:00 amRNSInterim Results for the six months to 31 Dec 2015
10th Feb 201612:11 pmRNSResult of AGM
25th Jan 20167:00 amRNSNet Asset Value(s)
22nd Dec 20157:00 amRNSAnnual Audited Results and Notice of AGM
17th Dec 20154:00 pmRNSDBC receives US FDA approval to market PulseFlowDF
4th Nov 20157:00 amRNSNet Asset Value(s)
30th Jul 20157:01 amRNSNet Asset Value(s)
15th Apr 20157:00 amRNSNet Asset Value as at 31 March 2015
30th Mar 20157:00 amRNSInterim results for 6 months to 31 December 2014
6th Feb 201512:21 pmRNSClose of Tender Offer
4th Feb 20155:36 pmRNSRe Results of Tender Offer
2nd Feb 20158:00 amRNSResults of Tender Offer
23rd Jan 20157:00 amRNSHolding(s) in Company
15th Jan 201511:56 amRNSHolding(s) in Company
14th Jan 20157:00 amRNSTender Offer
12th Jan 20159:32 amRNSNet Asset Value
30th Dec 20147:00 amRNSAnnual audited results
23rd Dec 201411:58 amRNSHolding(s) in Company
28th Nov 20142:04 pmRNSTender Offer in respect of Magna Biopharma
21st Oct 20147:00 amRNSNet Asset Value to 30 September 2014
22nd Jul 20147:00 amRNSNet Asset Value(s)
8th Apr 20147:00 amRNSNet Asset Value calculations to 31 March 2014
31st Mar 20147:00 amRNSInterim Results for the six months to 31 Dec 2013
24th Jan 201411:21 amRNSHolding(s) in Company
20th Jan 201410:56 amRNSHolding(s) in Company
17th Jan 20147:00 amRNSNet Asset Value(s)
15th Jan 20147:00 amRNSAppointment of Nominated Adviser
6th Jan 20145:49 pmRNSHolding(s) in Company
20th Nov 20134:04 pmRNSHolding(s) in Company
13th Nov 20135:13 pmRNSHolding(s) in Company
12th Nov 20137:00 amRNSResult of General Meeting
24th Oct 20137:01 amRNSNotice of General Meeting
24th Oct 20137:00 amRNSAnnual Financial Report
18th Oct 201311:23 amRNSHolding(s) in Company
18th Oct 20137:00 amRNSNet Asset Value(s)
4th Oct 20132:13 pmRNSHolding(s) in Company
26th Sep 20135:10 pmRNSHolding(s) in Company
13th Sep 201311:32 amRNSHolding(s) in Company
6th Sep 20135:29 pmRNSHolding(s) in Company
6th Aug 20139:40 amRNSHolding(s) in Company
11th Jul 20137:00 amRNSNet Asset Value(s)
15th Apr 201312:34 pmRNSDirectorate Change
12th Apr 20132:17 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.